<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35336934</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Cytolytic Properties and Genome Analysis of Rigvir<sup>&#xae;</sup> Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">525</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14030525</ELocationID><Abstract><AbstractText>Rigvir<sup>&#xae;</sup> is a cell-adapted, oncolytic virotherapy enterovirus, which derives from an echovirus 7 (E7) isolate. While it is claimed that Rigvir<sup>&#xae;</sup> causes cytolytic infection in several cancer cell lines, there is little molecular evidence for its oncolytic and oncotropic potential. Previously, we genome-sequenced Rigvir<sup>&#xae;</sup> and five echovirus 7 isolates, and those sequences are further analyzed in this paper. A phylogenetic analysis of the full-length data suggested that Rigvir<sup>&#xae;</sup> was most distant from the other E7 isolates used in this study, placing Rigvir<sup>&#xae;</sup> in its own clade at the root of the phylogeny. Rigvir<sup>&#xae;</sup> contained nine unique mutations in the viral capsid proteins VP1-VP4 across the whole data set, with a structural analysis showing six of the mutations concerning residues with surface exposure on the cytoplasmic side of the viral capsid. One of these mutations, E/Q/N162G, was located in the region that forms the contact interface between decay-accelerating factor (DAF) and E7. Rigvir<sup>&#xae;</sup> and five other isolates were also subjected to cell infectivity assays performed on eight different cell lines. The used cell lines contained both cancer and non-cancer cell lines for observing Rigvir<sup>&#xae;</sup>'s claimed properties of being both oncolytic and oncotropic. Infectivity assays showed that Rigvir<sup>&#xae;</sup> had no discernable difference in the viruses' oncolytic effect when compared to the Wallace prototype or the four other E7 isolates. Rigvir<sup>&#xae;</sup> was also seen infecting non-cancer cell lines, bringing its claimed effect of being oncotropic into question. Thus, we conclude that Rigvir<sup>&#xae;</sup>'s claim of being an effective treatment against multiple different cancers is not warranted under the evidence presented here. Bioinformatic analyses do not reveal a clear mechanism that could elucidate Rigvir<sup>&#xae;</sup>'s function at a molecular level, and cell infectivity tests do not show a discernable difference in either the oncolytic or oncotropic effect between Rigvir<sup>&#xae;</sup> and other clinical E7 isolates used in the study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hietanen</LastName><ForeName>Eero</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8548-3990</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Turku, 20520 Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Turku Doctoral Programme of Molecular Medicine, University of Turku, 20520 Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koivu</LastName><ForeName>Marika K A</ForeName><Initials>MKA</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Turku, 20520 Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Turku Doctoral Programme of Molecular Medicine, University of Turku, 20520 Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Turku Bioscience Centre, University of Turku, 20520 Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Susi</LastName><ForeName>Petri</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9245-3271</Identifier><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Turku, 20520 Turku, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Viruses. 2022 Sep 19;14(9):2076. doi: 10.3390/v14092076</RefSource><PMID Version="1">36146882</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Viruses. 2022 Sep 19;14(9):2078. doi: 10.3390/v14092078</RefSource><PMID Version="1">36146884</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D004267" MajorTopicYN="N">DNA Viruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014713" MajorTopicYN="Y">Viruses, Unclassified</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Rigvir&#xae;</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">echovirus</Keyword><Keyword MajorTopicYN="N">virotherapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35336934</ArticleId><ArticleId IdType="pmc">PMC8949920</ArticleId><ArticleId IdType="doi">10.3390/v14030525</ArticleId><ArticleId IdType="pii">v14030525</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kelly E., Russell S.J. History of Oncolytic Viruses: Genesis to Genetic Engineering. Mol. Ther. 2007;15:651&#x2013;659. doi: 10.1038/sj.mt.6300108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300108</ArticleId><ArticleId IdType="pubmed">17299401</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T.-C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 2007;4:101&#x2013;117. doi: 10.1038/ncponc0736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncponc0736</ArticleId><ArticleId IdType="pubmed">17259931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J.C.C., Coffin R.S., Davis C.J., Graham N.J., Groves N., Guest P.J., Harrington K.J., James N.D., Love C.A., McNeish I., et al. A Phase I Study of OncoVEX GM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor. Clin. Cancer Res. 2006;12:6737&#x2013;6747. doi: 10.1158/1078-0432.CCR-06-0759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-06-0759</ArticleId><ArticleId IdType="pubmed">17121894</ArticleId></ArticleIdList></Reference><Reference><Citation>Conry R.M., Westbrook B., McKee S., Norwood T.G. Talimogene laherparepvec: First in class oncolytic virotherapy. Hum. Vaccin. Immunother. 2018;14:839&#x2013;846. doi: 10.1080/21645515.2017.1412896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1412896</ArticleId><ArticleId IdType="pmc">PMC5893211</ArticleId><ArticleId IdType="pubmed">29420123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yl&#xe4;-Pelto J., Tripathi L., Susi P. Therapeutic Use of Native and Recombinant Enteroviruses. Viruses. 2016;8:57. doi: 10.3390/v8030057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8030057</ArticleId><ArticleId IdType="pmc">PMC4810247</ArticleId><ArticleId IdType="pubmed">26907330</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy C., Jayawardena N., Burga L.N., Bostina M. Developing Picornaviruses for Cancer Therapy. Cancers. 2019;11:685. doi: 10.3390/cancers11050685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11050685</ArticleId><ArticleId IdType="pmc">PMC6562951</ArticleId><ArticleId IdType="pubmed">31100962</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren D.R., Au G.G., Nguyen T., Newcombe N.G., Haley E.S., Beagley L., Johansson E.S., Hersey P., Barry R.D. Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21. Clin. Cancer Res. 2004;10:53&#x2013;60. doi: 10.1158/1078-0432.CCR-0690-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-0690-3</ArticleId><ArticleId IdType="pubmed">14734451</ArticleId></ArticleIdList></Reference><Reference><Citation>Au G.G., Lincz L.F., Enno A., Shafren D.R. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br. J. Haematol. 2007;137:133&#x2013;141. doi: 10.1111/j.1365-2141.2007.06550.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2007.06550.x</ArticleId><ArticleId IdType="pubmed">17391493</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry L.J., Au G.G., Barry R.D., Shafren D.R. Potent Oncolytic activity of human enteroviruses against human prostate cancer. Prostate. 2008;68:577&#x2013;587. doi: 10.1002/pros.20741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.20741</ArticleId><ArticleId IdType="pubmed">18288643</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Pe&#xf1;aranda S., Maher K., Pallansch M.A. Complete genome sequences of all members of the species Human enterovirus A. J. Gen. Virol. 2004;85:1597&#x2013;1607. doi: 10.1099/vir.0.79789-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell R., Delwart E., Gorbalenya A.E., Hovi T., King A.M.Q., Knowles N.J., Lindberg A.M., Pallansch M.A., Palmenberg A.C., Reuter G., et al. ICTV Virus Taxonomy Profile: Picornaviridae. J. Gen. Virol. 2017;98:2421&#x2013;2422. doi: 10.1099/jgv.0.000911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000911</ArticleId><ArticleId IdType="pmc">PMC5725991</ArticleId><ArticleId IdType="pubmed">28884666</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacques J., Moret H., Minette D., L&#xe9;v&#xea;que N., Jovenin N., Desl&#xe9;e G., Lebargy F., Motte J., Andr&#xe9;oletti L. Epidemiological, Molecular, and Clinical Features of Enterovirus Respiratory Infections in French Children between 1999 and 2005. J. Clin. Microbiol. 2008;46:206&#x2013;213. doi: 10.1128/JCM.01414-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01414-07</ArticleId><ArticleId IdType="pmc">PMC2224256</ArticleId><ArticleId IdType="pubmed">18003804</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S., Paananen A., Savolainen-Kopra C., Hovi T., Roivainen M. Eight Years of Experience with Molecular Identification of Human Enteroviruses. J. Clin. Microbiol. 2008;46:2410&#x2013;2413. doi: 10.1128/JCM.00313-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00313-08</ArticleId><ArticleId IdType="pmc">PMC2446933</ArticleId><ArticleId IdType="pubmed">18463218</ArticleId></ArticleIdList></Reference><Reference><Citation>Benschop K.S.M., van der Avoort H.G., Jusic E., Vennema H., van Binnendijk R., Duizer E. Polio and Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015. Appl. Environ. Microbiol. 2017;83:e00558-17. doi: 10.1128/AEM.00558-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00558-17</ArticleId><ArticleId IdType="pmc">PMC5478994</ArticleId><ArticleId IdType="pubmed">28432101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C., Bergelson J.M. Echovirus 7 entry into polarized intestinal epithelial cells requires clathrin and Rab7. MBio. 2012;3:1&#x2013;10. doi: 10.1128/mBio.00304-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00304-11</ArticleId><ArticleId IdType="pmc">PMC3324788</ArticleId><ArticleId IdType="pubmed">22496312</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill T.J., Groppelli E., Hogle J.M., Rowlands D.J. Cell Entry by Non-Enveloped Viruses. Springer; Berlin/Heidelberg, Germany: 2010. Picornaviruses; pp. 43&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts P., Tilgase A., Rasa A., Bandere K., Venskus D. The advent of oncolytic virotherapy in oncology: The Rigvir&#xae; story. Eur. J. Pharmacol. 2018;837:117&#x2013;126. doi: 10.1016/j.ejphar.2018.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2018.08.042</ArticleId><ArticleId IdType="pubmed">30179611</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigvir Therapeutic Characteristics.  [(accessed on 19 February 2022)].  Available online:  https://www.rigvir.com/products/rigvir.php.</Citation></Reference><Reference><Citation>Alberts P., Olmane E., Brok&#x101;ne L., Krasti&#x146;a Z., Romanovska M., Kup&#x10d;s K., Isajevs S., Proboka G., Erdmanis R., Nazarovs J., et al. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS. 2016;124:896&#x2013;904. doi: 10.1111/apm.12576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.12576</ArticleId><ArticleId IdType="pubmed">27457663</ArticleId></ArticleIdList></Reference><Reference><Citation>Donin&#x105; S., Strele I., Proboka G., Auzi&#x146;&#x161; J., Alberts P., Jonsson B., Venskus D., Muceniece A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25:421&#x2013;426. doi: 10.1097/CMR.0000000000000180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CMR.0000000000000180</ArticleId><ArticleId IdType="pmc">PMC4560272</ArticleId><ArticleId IdType="pubmed">26193376</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenert D.C., Basbaum C.B., Welsh M.J., Li M., Finkbeiner W.E., Nadel J.A. Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc. Natl. Acad. Sci. USA. 1988;85:5951&#x2013;5955. doi: 10.1073/pnas.85.16.5951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.16.5951</ArticleId><ArticleId IdType="pmc">PMC281883</ArticleId><ArticleId IdType="pubmed">2457904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Stringer C., Wang T., Michaelos M., Pachitariu M. Cellpose: A generalist algorithm for cellular segmentation. Nat. Methods. 2021;18:100&#x2013;106. doi: 10.1038/s41592-020-01018-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-020-01018-x</ArticleId><ArticleId IdType="pubmed">33318659</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltola V., Waris M., Osterback R., Susi P., Ruuskanen O., Hyypi&#xe4; T. Rhinovirus transmission within families with children: Incidence of symptomatic and asymptomatic infections. J. Infect. Dis. 2008;197:382&#x2013;389. doi: 10.1086/525542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/525542</ArticleId><ArticleId IdType="pubmed">18248302</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;nnrot M., Sj&#xf6;roos M., Salminen K., Maaronen M., Hyypi&#xe4; T., Hy&#xf6;ty H. Diagnosis of enterovirus and rhinovirus infections by RT-PCR and time-resolved fluorometry with lanthanide chelate labeled probes. J. Med. Virol. 1999;59:378&#x2013;384. doi: 10.1002/(SICI)1096-9071(199911)59:3&lt;378::AID-JMV19&gt;3.0.CO;2-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199911)59:3&lt;378::AID-JMV19&gt;3.0.CO;2-I</ArticleId><ArticleId IdType="pubmed">10502272</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish N.J., Witteveldt J., Clasper L., McIntyre C., McWilliam Leitch E.C., Hardie A., Bennett S., Gunson R., Carman W.F., Feeney S.A., et al. Development and Assay of RNA Transcripts of Enterovirus Species A to D, Rhinovirus Species A to C, and Human Parechovirus: Assessment of Assay Sensitivity and Specificity of Real-Time Screening and Typing Methods. J. Clin. Microbiol. 2012;50:2910&#x2013;2917. doi: 10.1128/JCM.01172-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01172-12</ArticleId><ArticleId IdType="pmc">PMC3421820</ArticleId><ArticleId IdType="pubmed">22740708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietanen E., Smura T., Hakanen M., Chansaenroj J., Merilahti P., Nevalainen J., Pandey S., Koskinen S., Tripathi L., Poovorawan Y., et al. Genome Sequences of RIGVIR Oncolytic Virotherapy Virus and Five Other Echovirus 7 Isolates. Genome Announc. 2018;6:7&#x2013;8. doi: 10.1128/genomeA.00317-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/genomeA.00317-18</ArticleId><ArticleId IdType="pmc">PMC5920193</ArticleId><ArticleId IdType="pubmed">29700151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua B.H., McMinn P.C., Lam S.K., Chua K.B. Comparison of the complete nucleotide sequences of echovirus 7 strain UMMC and the prototype (Wallace) strain demonstrates significant genetic drift over time. J. Gen. Virol. 2001;82:2629&#x2013;2639. doi: 10.1099/0022-1317-82-11-2629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-82-11-2629</ArticleId><ArticleId IdType="pubmed">11602774</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792&#x2013;1797. doi: 10.1093/nar/gkh340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh340</ArticleId><ArticleId IdType="pmc">PMC390337</ArticleId><ArticleId IdType="pubmed">15034147</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh K., Standley D.M. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability. Mol. Biol. Evol. 2013;30:772&#x2013;780. doi: 10.1093/molbev/mst010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/mst010</ArticleId><ArticleId IdType="pmc">PMC3603318</ArticleId><ArticleId IdType="pubmed">23329690</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Meng E.C., Couch G.S., Croll T.I., Morris J.H., Ferrin T.E. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70&#x2013;82. doi: 10.1002/pro.3943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3943</ArticleId><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Hafenstein S., Harris K.G., Cifuente J.O., Zhang Y., Bowman V.D., Chipman P.R., Bator C.M., Lin F., Medof M.E., et al. Interaction of Decay-Accelerating Factor with Echovirus 7. J. Virol. 2010;84:12665&#x2013;12674. doi: 10.1128/JVI.00837-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00837-10</ArticleId><ArticleId IdType="pmc">PMC3004353</ArticleId><ArticleId IdType="pubmed">20881044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilgase A., Patetko L., Bl&#x101;&#x137;e I., Ramata-Stunda A., Borodu&#x161;&#x137;is M., Alberts P. Effect of the oncolytic ECHO-7 virus Rigvir&#xae; on the viability of cell lines of human origin in vitro. J. Cancer. 2018;9:1033&#x2013;1049. doi: 10.7150/jca.23242.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.23242</ArticleId><ArticleId IdType="pmc">PMC5868171</ArticleId><ArticleId IdType="pubmed">29581783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gullberg M., Tolf C., Jonsson N., Polacek C., Precechtelova J., Badurova M., Sojka M., Mohlin C., Israelsson S., Johansson K., et al. A Single Coxsackievirus B2 Capsid Residue Controls Cytolysis and Apoptosis in Rhabdomyosarcoma Cells. J. Virol. 2010;84:5868&#x2013;5879. doi: 10.1128/JVI.02383-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02383-09</ArticleId><ArticleId IdType="pmc">PMC2876633</ArticleId><ArticleId IdType="pubmed">20375176</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S., Petty T.J., Schibler M., Martinez Y., Gerlach D., van Belle S., Turin L., Zdobnov E., Kaiser L., Tapparel C. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog. 2012;8:19. doi: 10.1371/journal.ppat.1002826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Tan K.O., Othman I., Poh C.L. Identification of molecular determinants of cell culture growth characteristics of Enterovirus 71. Virol. J. 2016;13:194. doi: 10.1186/s12985-016-0645-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0645-9</ArticleId><ArticleId IdType="pmc">PMC5126835</ArticleId><ArticleId IdType="pubmed">27894305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Mohamed R.A.H., Ong S.-K., Tan K.O., Poh C.L. Characterization of significant molecular determinants of virulence of Enterovirus 71 sub-genotype B4 in Rhabdomyosarcoma cells. Virus Res. 2017;238:243&#x2013;252. doi: 10.1016/j.virusres.2017.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.07.010</ArticleId><ArticleId IdType="pubmed">28705680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikesch J.-H., Buerger H., Simon R., Brandt B. Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies. Biochim. Biophys. Acta-Rev. Cancer. 2006;1766:42&#x2013;52. doi: 10.1016/j.bbcan.2006.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2006.04.001</ArticleId><ArticleId IdType="pubmed">16784816</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G., Arnold E., Erickson J.W., Frankenberger E.A., Griffith J.P., Hecht H.J., Johnson J.E., Kamer G., Luo M., Mosser A.G. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985;317:145&#x2013;153. doi: 10.1038/317145a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/317145a0</ArticleId><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelsson S., Jonsson N., Gullberg M., Lindberg A.M. Cytolytic replication of echoviruses in colon cancer cell lines. Virol. J. 2011;8:473. doi: 10.1186/1743-422X-8-473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-473</ArticleId><ArticleId IdType="pmc">PMC3213228</ArticleId><ArticleId IdType="pubmed">21999585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>